Health Data Insight CIC’s Post

👩🔬 OF COURSE healthcare providers NEED a patient's labs before prescribing a GLP-1 receptor agonist! Labs are part of the comprehensive evaluation that is a critical part of EVIDENCE-BASED OBESITY MEDICINE. We need a lot of data to determine if someone is a good or bad candidate for ANY MEDICATION we prescribe. GLP-1 medications are no different, and in fact, they are very POWERFUL medications that can be DANGEROUS for poorly selected patients. GLP-1 prescribing should not be taken lightly!! 🎤 Thanks Madison Muller for reporting on the topic. It's not surprising that labs are monetizing the obesity work up. 📰 Madison's Bloomberg article: https://lnkd.in/er7s4tTW Photographer: Noriko Hayashi/Bloomberg 📰 My recent Healio article "New anti-obesity medications: With great power comes great responsibility": https://lnkd.in/eUTsMXsF 👨💼 One patient story that I shared with Madison: “I have one patient who was extremely frustrated about our lab requirement. Then his labs ended up leading to a rare cancer diagnosis.” I think about this dear patient every day. We are so fortunate that his obesity labs led to an early cancer diagnosis. Intellihealth #FlyteMedical #obesity #labs

Treating patients with superficial venous thrombosis? Than most likely you work in primary care and often feel doubt on whether or not to treat these patients with anticoagulants. Yes, there is a small yet substantial risk of #deepveinthrombosis and #pulmonaryembolism, but also likely most patients fare well without anticoagulants and 'watchful waiting'. We recently conducting a systematic review and meta-analysis on this topic, published now online in #bmjopen; here is what we found: - Evidence is poor, high variability among studies, poor methods - From what we found, high age, male sex, history of VTE, cancer and absence of varicoses seem to predict clot propagation - Multivariable models of high quality are needed; we are currently underway with such a study in primary care date, so keep tuned! Circulatory Health UMC Utrecht Florien van Royen Frans Rutten Sander van Doorn Maarten van Smeden Want to read more? See link: https://lnkd.in/eSfNgc2A

Discover how ECOG Performance Status impacts the prognosis of patients with acute PE and malignancy. The study reveals the significance of ECOG PS ≥ 3 in predicting mortality. #AcutePE #CancerCare #ECOGPerformanceStatus #cureus 🔗 Read more: https://bit.ly/3SCDE8U

Unveiling Patient Patterns to Transform ALS Care Understanding how diseases progress in different patients is crucial for better treatment and care. Imagine if we could sort patients into groups based on their unique disease journeys. That's exactly what the new approach, ClusTric, aims to do! ClusTric uses advanced data techniques, combining triclustering and hierarchical clustering, to uncover complex patterns in disease progression that simpler methods miss. This approach is especially valuable for conditions like Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease with unpredictable and varied progression. In a fascinating case study, researchers applied ClusTric to patient data from the Lisbon ALS Clinic and validated it with clinical trial data. They discovered four distinct ALS progression groups: slow progressors, moderate bulbar and spinal progressors, and fast progressors. This stratification can guide personalized clinical decisions and improve patient care. Compared to other top methods, ClusTric proved more effective in capturing the diverse progression of ALS with fewer, but more clinically relevant, patient groups. This breakthrough in understanding ALS progression patterns is a game-changer, paving the way for tailored treatments and better outcomes for patients. #ALSResearch #PatientCare #DataScience #MedicalInnovation #PersonalizedMedicine #DiseaseProgression #ClusTric #HealthcareTransformation https://lnkd.in/dFQRahRD

Thank you so much Katherine Saunders, MD for underscoring the NEED for labs! In the "Wild West" world of online incretin mimetic pushers masquerading as virtual obesity medicine clinics, labs are generally considered to be a nuisance -- an inconvenient "friction point" in the sales conversion process. In the "How it works" section on any of these sites, the topic of blood testing is either ignored entirely or briefly mentioned as a possibility. The "How it works" section of the Ro Body https://ro.co/weight-loss/ Program site, for example, starts with the following sentence: "We’re pushing every day to get medication to our patients faster." And mentions lab testing in the form of a warning: "If your provider orders a lab test, it may extend the timeline..." The unspoken message is clearly: Hey, if you want us to get these meds to you as fast as possible, see what you can do to convince your provider to nix the labs!

Overcoming Racial and Ethnic Biases in the Diagnosis of Patients With Alpha-1 Antitrypsin Deficiency in the United States Using a Machine-Learning Model. The Objective: To develop a prediction model to identify symptomatic patients of different races and ethnicities with likely risk of AATD using claims data from a large US database. Implicit and explicit biases are among many factors that contribute to disparities in health and health care. (Tackling Implicit Bias in Health Care Published July 9, 2022 N Engl J Med 2022;387:105-107 DOI: 10.1056/NEJMp2201180 ) In partnership with Takeda, we took to designing a machine learning process to find likely candidates and overcome racial biases in the detection of this disease that may result in serious lung or liver disease. AATD is largely underdiagnosed, with an estimated prevalence of 100,000 individuals with AATD in the US; however, fewer than 10,000 individuals are diagnosed (Ashenhurst JR, et al. Chest. 2022;161(2):373-381.) Previously, AATD was thought to affect only White individuals of European descent. Recent studies have shown that people of different races and ethnicities have genotypes consistent with those with moderate-to-severe AATD-related lung disease. (Quinn M, et al. Ther Clin Risk Manag. 2020;16:1243-1255. de Serres FJ, Blanco I. Ther Adv Respir Dis. 2012;6(5):277-295.) The Process: Data from the Komodo Health US claims database (April 26, 2016 to January 31, 2023) were divided into “positive,” “negative,” and “target” cohorts. A machine-learning model for detecting AATD was trained on positive and negative cohorts without using codes revealing AATD diagnosis and treatment.The learned model was applied to the target cohort to flag patients with likely undiagnosed AATD. Results: This approach produced a highly performant prediction model capable of detecting undiagnosed people living with AATD, validated by expert clinicians. (For a deeper look at how this unique ML process could be applied to other indications, please message us directly.)

Discover how ECOG Performance Status impacts the prognosis of patients with acute PE and malignancy. The study reveals the significance of ECOG PS ≥ 3 in predicting mortality. #AcutePE #CancerCare #ECOGPerformanceStatus #cureus 🔗 Read more: https://bit.ly/3SCDE8U

New analysis from the #LIPIDOGRAM & #LIPIDOGEN2015 studies. Using the hierarchical cluster analysis we identified the #phenotypes that have the highest #mortality risk in #primarycare settings. In primary care, the practice of providing appropriate #prevention strategies to high-risk patients is increasingly recognized as an important #strategy for improving patient care and outcomes, to help optimize the allocation of medical resources and more focus on #patients at higher risk of adverse health #events. However, challenges still remain in implementing #riskstratification in primary care. Our conclusion that primary care physicians should focus on #overweight/#obesity #older patients with multiple comorbidities may seem intuitive, but it was confirmed by the scientific hierarchical cluster analysis, providing a potential technical rationale for the further development of more advanced and nuanced risk stratification implementations. Additionally, our study demonstrates that protein thiol groups (#PSH) partially might contribute to the high-risk mortality in overweight/obesity older patients. Given the potential of PSH in assessing #oxidativestress status and predicting all-cause mortality, further studies are warranted. Interestingly, #young group population overweight/obesity does not significantly increase the risk in the long-term follow-up, thus providing a basis for stratified management of the risk of all-cause #mortality. It was next amazing scientific adventure with this data. Thanks to all co-authors - amazing collaboration with #LCCS. 💪 More soon to come 💪 Yang Chen, Ying Gue, Peter P. Toth, MD, PhD, Marek Gierlotka https://lnkd.in/d7ZbhtUu

🔬 2024 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 #MDS 𝐂𝐥𝐚𝐬𝐬𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧: 2022 marked a major step in MDS classification with the introduction of International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. Published in the 𝐁𝐥𝐨𝐨𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐉𝐨𝐮𝐫𝐧𝐚𝐥 in 𝐀𝐩𝐫𝐢𝐥 2024, new research proposes integrating both systems to enhance the diagnosis and treatment of Myelodysplastic Syndromes (MDS) in the future. 👉 Read more about this research and further analysis here: https://lnkd.in/giendMqD #BloodCancer #MedicalResearch

This morning, our team(Kunal Lodaya, MD) at #ISPORAnnual presents the poster (EPH124; 3036) entitled “Examining the Effect of Hypertension, Type-2 Diabetes Mellitus, Hyperlipidemia and Obesity on Endometrial Cancer Staging Machine.” ISPOR—The Professional Society for Health Economics and Outcomes Research Uterine #EndometrialCancer (#EC) is the most prevalent gynecologic malignancy in the U.S. and a significant cause of morbidity and mortality. This cross-sectional #Retrospective #RealWorldEvidence study used an extensive U.S. healthcare database to examine the relationship between common #Comorbidities, sociodemographic characteristics, total patient cost, and endometrial cancer progression. A total of 9,615 participants were included in the study. We found significant associations between pre-existing #Hypertension, #Type2Diabetes, #Hyperlipidemia, and morbid #Obesity with the progression to stage IV endometrial cancer. To learn more about this study and others, please visit Boston Strategic Partners at Booth 618. For further information about our presentations, visit www.ispor.org/ISPOR2024  #CancerAwareness #UterineCancer